Loading clinical trials...

Increasing Use of Continuous Glucose Monitors in Publicly-insured Youth With Type 1 Diabetes | Clinical Trials | Clareo Health

TERMINATEDNA

Increasing Use of Continuous Glucose Monitors in Publicly-insured Youth With Type 1 Diabetes

Improving Adherence to Continuous Glucose Monitors in Publicly-insured Youth With Type 1 Diabetes

NCT03297762•Stanford University

View on ClinicalTrials.gov

Summary

To use an enhanced continuous glucose monitor (CGM) experience, including an automated CGM-electronic health record (EHR) data integration system, proactive interventions, and gamification techniques, to increase CGM use among publicly-insured youth with type 1 diabetes (T1D).

Detailed Description

The investigators will use an automated data integration system to monitor hours per week the CGM is worn and target interventions/troubleshooting techniques as needed. The investigators will use gamification techniques (i.e. ability to gain points and achieve small rewards) to help encourage CGM use and potentially improve glycemic control in this at-risk population.

Eligibility

Age

13 - 19 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•type 1 diabetes for more than 6 months
•on insulin pump or multiple daily injections without plans to change modality in next 6 months
•insured by CCS or Medi-Cal
•receiving care at Lucile Packard Children's Hospital or Stanford Children's Health outpatient clinics
•English or Spanish-speaking

Exclusion Criteria

•major illness or condition that may alter glucose control or ability to complete the study including pregnancy, cystic fibrosis, cancer, liver disease, history of transplant, or hemoglobinopathy
•current oral glucocorticoid use
•prior use of a CGM system
•hemoglobin A1C \<7.5% or \>12%
•no wireless internet access

Locations (1)

Stanford Children's

Stanford, California, United States

Key Dates

Start Date

May 7, 2018

Primary Completion Date

May 1, 2019

Completion Date

June 1, 2019

Last Updated

April 20, 2020

Enrollment

ACTUAL participants

Conditions

Type1diabetes

Interventions

gamification

BEHAVIORAL

Use of Dexcom G5

BEHAVIORAL

Crosstalk Between Mucosal-Associated Invariant T (MAIT) Cells and the Gut Microbiota and Mucosa in the Development of Type 1 Diabetes in Children

NCT05054361

Type1diabetes

View study

RECRUITINGPHASE1

Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 Inhibitors

NCT06753994

DiabetesType1diabetes+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 20, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Increasing Use of Continuous Glucose Monitors in Publicly-insured Youth With Type 1 Diabetes

Inclusion Criteria

Exclusion Criteria

Crosstalk Between Mucosal-Associated Invariant T (MAIT) Cells and the Gut Microbiota and Mucosa in the Development of Type 1 Diabetes in Children

Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 Inhibitors

Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents

Screening for Islet Autoantibodies in the Israeli Paediatric General Population for Detection of Pre-symptomatic Type-1 Diabetes Mellitus

Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes

Advanced Glycation Products and Vascular Complications in Type 1 Diabetes